Status: Recruiting
Phase II Clinical Study of HRS-9563 in Patients With Mild to Moderate Hypertension
This study aims to evaluate the efficacy and safety of HRS-9563 in patients with mild to moderate hypertension, and to explore its appropriate dosage.
Participants needed: 234
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Fujian Shengdi Pharmaceutical Co., Ltd.Updated: Jan 26, 2026Locations: 1
Eligibility criteria
The subject voluntarily signs the informed consent form. [+3]
Secondary hypertension; [+8]